Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Articles by Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Third and Subsequent Line Options for Multiple Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Updates in Relapsed/Refractory Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Updates in Multiple Myeloma in the Frontline Setting

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Latest Updated Articles

Updates in Multiple Myeloma in the Frontline Setting
January 29th 2021
$Updates in Relapsed/Refractory Myeloma$
Updates in Relapsed/Refractory Myeloma
January 29th 2021
Third and Subsequent Line Options for Multiple Myeloma
January 29th 2021

Trending on OncLive

FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026

Five Under 5: Top Oncology Videos for the Week of 10/12

Early-Phase INCA33890 Data Lay the Foundation for Phase 3 Combination Research in MSS CRC

Talquetamab Plus Daratumumab Earns CHMP Backing in R/R Myeloma